Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Instagram Outage Disrupts Thousands of U.S. Users 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
NEW YORK, March 31, 2017 -- Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that Adnan Butt will join the firm as a Managing Director to expand Healthcare coverage on the Equities platform. Mr. Butt will join Guggenheim on the Healthcare research team in June, specifically focusing on biotechnology companies.
Mr. Butt joins Guggenheim from RBC Capital Markets, where he was a Biotechnology Analyst. Prior to RBC, he covered biotechnology at ThinkEquity Partners, Morgan Stanley, and J.P. Morgan & Co.
“We are excited for Adnan to join our team,” said Jerry Donini, Co-CEO of Guggenheim Securities. “His deep industry knowledge provides a significant expansion to our Healthcare platform, building on our existing research presence in specialty pharmaceuticals, major pharmaceuticals, biotechnology, and medical devices and supplies. We look forward to his success at Guggenheim.”
Mr. Butt received his M.A. in Economics from Trinity College and his M.A. in Neuroscience from the University of Hartford; he received his B.A. in Economic and Molecular Biology & Biochemistry from Wesleyan University. He will be based in Guggenheim’s San Francisco office.
About Guggenheim Partners
Guggenheim Partners is a global investment and advisory firm with more than $260 billion1 in assets under management. Across our three primary businesses of investment management, investment banking, and insurance services, we have a track record of delivering results through innovative solutions. With more than 2,300 professionals based in more than 25 offices around the world, our commitment is to advance the strategic interests of our clients and to deliver long-term results with excellence and integrity. We invite you to learn more about our expertise and values by visiting GuggenheimPartners.com and following us on Twitter at twitter.com/guggenheimptnrs.
1 Assets under management are as of 12.31.2016 and include consulting services for clients whose assets are valued at approximately $63bn.
Media Contact Ellen Cunningham Guggenheim Partners 212.518.9578 [email protected]
